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Background: Human multiple myeloma (MM) is an incurable hematological malignancy for which novel therapeutic
agents are needed. Calmodulin (CaM) antagonists have been reported to induce apoptosis and inhibit tumor cell
invasion and metastasis in various tumor models. However, the antitumor effects of CaM antagonists on MM are poorly
understood. In this study, we investigated the antitumor effects of naphthalenesulfonamide derivative selective CaM
antagonists W-7 and W-13 on MM cell lines both in vitro and in vivo.
Methods: The proliferative ability was analyzed by the WST-8 assay. Cell cycle was evaluated by flow cytometry
after staining of cells with PI. Apoptosis was quantified by flow cytometry after double-staining of cells by Annexin-V/PI.
Molecular changes of cell cycle and apoptosis were determined by Western blot. Intracellular calcium levels and
mitochondrial membrane potentials were determined using Fluo-4/AM dye and JC-10 dye, respectively. Moreover,
we examined the in vivo anti-MM effects of CaM antagonists using a murine xenograft model of the human MM
cell line.
Results: Treatment with W-7 and W-13 resulted in the dose-dependent inhibition of cell proliferation in various MM cell
lines. W-7 and W-13 induced G1 phase cell cycle arrest by downregulating cyclins and upregulating p21cip1. In
addition, W-7 and W-13 induced apoptosis via caspase activation; this occurred partly through the elevation of
intracellular calcium levels and mitochondrial membrane potential depolarization and through inhibition of the
STAT3 phosphorylation and subsequent downregulation of Mcl-1 protein. In tumor xenograft mouse models,
tumor growth rates in CaM antagonist-treated groups were significantly reduced compared with those in the
vehicle-treated groups.
Conclusions: Our results demonstrate that CaM antagonists induce cell cycle arrest, induce apoptosis via caspase
activation, and inhibit tumor growth in a murine MM model and raise the possibility that inhibition of CaM might
be a useful therapeutic strategy for the treatment of MM.
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Multiple myeloma (MM) is a hematological malig-
nancy characterized by the excess accumulation of
plasma cells in the bone marrow and the production of
monoclonal immunoglobulins or paraproteins [1]. Des-
pite conventional therapies including alkylating agents,* Correspondence: yokokura@med.kagawa-u.ac.jp
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unless otherwise stated.anthracyclines, and corticosteroids [2,3] as well as in-
tensive therapies, including autologous hematopoietic
stem cell transplantation [4] and the novel agents bortezo-
mib, thalidomide, and lenalidomide [5-7], the incurable
nature of MM continues to stimulate the investigation of
novel drugs.
Calmodulin (CaM), an ubiquitous intracellular calcium-
sensing protein, mediates the effects of changes in the
cytoplasmic Ca2+ level and is involved in the regulation of
many biological processes. In particular, CaM has beenal Ltd. This is an Open Access article distributed under the terms of the Creative
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and apoptosis regulation. In cell cycle progression, the
concentration of CaM progressively increases, reaches
high levels at the G1/S transition, and remains high during
the ensuing progression of the cell cycle. In apoptosis
regulation, CaM regulates apoptotic processes both posi-
tively and negatively mediating elevated intracellular Ca2+,
which can have both growth promoting and cell death-
inducing consequences [8]. CaM has also been reported
to be highly expressed in mRNA level in MM cells com-
pared with normal plasma cells in the identical twins
study [9], and the mRNA expression level of CaM has
shown to be higher in plasma cells in the patients of
monoclonal gammopathy of undetermined significance
compared with normal plasma cells [10]. There is evi-
dence that specific antagonists of CaM inhibit the growth
of a variety of tumor cells, such as lung cancer cells, breast
cancer cells, and cholangiocarcinoma cells [11-13]. CaM
antagonists also reduce cell invasion in human melan-
oma cell lines [14] and Lewis lung carcinoma-induced
lung metastasis [15]. However, neither the in vitro nor
in vivo antitumor effects of CaM antagonists on MM
are well understood.
In this study, we investigated the effects of the naphtha-
lenesulfonamide derivatives W-7 and W-13, selective and
cell-permeable CaM antagonists, on proliferation, cell
cycle progression, and apoptosis in human MM cell
lines. Furthermore, we demonstrated that CaM antago-
nists inhibited human MM tumor growth in xenografted
mouse models. These studies suggest that inhibition




Rabbit anti-cyclin D1 polyclonal antibody, rabbit anti-
cyclin D2 (D52F9) monoclonal antibody, mouse anti-cyclin
E1 (HE12) monoclonal antibody, rabbit anti-cyclin-
dependent kinase (CDK) 2 (78B2) monoclonal antibody,
mouse anti-CDK4 (DCS156) monoclonal antibody, mouse
anti-CDK6 (DCS83) monoclonal antibody, mouse anti-
retinoblastoma protein (Rb) (4H1) monoclonal antibody,
rabbit anti-phospho-Rb (Ser795) polyclonal antibody,
rabbit anti-p21cip1 (12D1) monoclonal antibody, rabbit
anti-p27kip1 polyclonal antibody, rabbit anti-caspase-9
polyclonal antibody, rabbit anti-cleaved caspase-9 (Asp330)
polyclonal antibody, rabbit anti-caspase-8 (D35G2) mono-
clonal antibody, rabbit anti-cleaved caspase-8 (Asp391)
monoclonal antibody, rabbit anti-caspase-3 polyclonal anti-
body, rabbit anti-cleaved caspase-3 (Asp175) monoclo-
nal antibody, rabbit anti-caspase-7 polyclonal antibody,
rabbit anti-cleaved caspase-7 (Asp198) polyclonal antibody,
rabbit anti-PARP polyclonal antibody, rabbit anti-STAT3
(79D7) monoclonal antibody, rabbit anti-phospho-STAT3(Tyr705) polyclonal antibody, and rabbit anti-Mcl-1
polyclonal antibody were obtained from Cell Signaling
Technology (Beverly, MA) and mouse anti-GAPDH
(0411) monoclonal antibody, rabbit anti-ERK1/2 (H-72)
polyclonal antibody, and goat anti-phospho-ERK1/2
(Thr 202/Tyr204) polyclonal antibody were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-
calmodulin (Ab-79/81) polyclonal antibody was purchased
from Assay Biotechnology Company Inc. (Sunnyvale, CA)
W-5, W-7, and W-13 were purchased from Tokyo Kasei
Industry (Tokyo, Japan).
Cells and cell culture
Human MM cell lines RPMI 8226, U266, MM1.S, and
MM1.R were purchased from the American Type Culture
Collection (ATCC, Manassas, VA), and KMS-5, KMS-
12-BM, and NCI-H929 lines were kindly provided by
Dr. Kensuke Matsumoto (Institute of Internal Medicine,
Faculty of Medicine, Kagawa University, Japan). All cell
lines were recharacterized by short tandem repeat pro-
filing to confirm no cross-contamination. All cell lines
except KMS-12-BM and NCI-H929 were maintained in
RPMI 1640 medium (Life Technologies, Carlsbad, CA)
with 10% fetal bovine serum (FBS; Life Technologies),
100 U/mL of penicillin (Wako, Osaka, Japan), and
100 μg/mL of streptomycin (Sigma-Aldrich Corpor-
ation, St. Louis, MO) and were cultured at 37°C. For
the KMS-12-BM and NCI-H929 lines, 0.05 mM of 2-
mercaptoethanol was added to the culture medium
described above.
Cell proliferation assay
MM cells were seeded in a 96-well plate at a density of
20,000 cells/well in 100 μL of culture medium; the cells
were maintained at 37°C for 24 h in the presence of vari-
ous concentrations (0–80 μM) of W-5, W-7, or W-13.
This culture step was followed by 3 h incubation with
10 μL of WST-8 labeling reagent (Cell Counting Kit-8;
Dojindo, Kumamoto, Japan), after which the absorbance
at 450 nm was read on a microplate reader.
Cell cycle analysis
MM cells (1 × 106/well) were cultured in the presence or
absence of CaM antagonists for 24 h. The cells were
washed, fixed in ethanol for 2 h, and stained with propi-
dium iodide using a Cell Cycle Phase Determination Kit
(Cayman Chemical, Ann Arbor, MI) according to the
manufacturer’s protocol. The samples were analyzed on
a Cytomics FC 500 flow cytometer (Beckman Coulter)
with a 488-nm excitation laser. Live cells were gated ac-
cording to the forward and side scatter profiles. The per-
centage of cells in each phase of the cell cycle was
calculated using MultiCycle AV software (Phoenix Flow
Systems, San Diego, CA).
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MM cells (1 × 106/well) were treated with or without CaM
antagonists for 24 h. The cells were then incubated with
FITC-annexin V and propidium iodide (Alexa Fluor 488
Annexin V/Dead Cell Apoptosis kit; Life Technologies,
Eugene, OR) according to the manufacturer’s protocol.
Apoptosis was subsequently assessed by flow cytometry.
Using flow cytometric analysis plots of cells with annexin-
V on the x-axis and propidium iodide on the y-axis, the
percentages of the cell population were determined for
each of the following quadrants: lower left, normal cells;
lower right, early apoptotic cells; upper right, late apop-
totic and necrotic cells.
Western blot analysis
For each condition, 5 × 106 cells were cultured with or
without CaM antagonists for 24 h. The cells were lysed
in RIPA buffer (Thermo Scientific, Rockford, IL) in the
presence of protease and phosphatase inhibitor cocktail
(Thermo Scientific). The proteins were separated on an
acrylamide gel and transferred onto a polyvinylidene
difluoride membrane (Bio-Rad, Hercules, CA). The
membranes were then blocked for 1 h in PBS containing
5% non-fat dried milk and 0.05% Tween-20, followed by an
incubation of several hours with primary antibodies. The
membranes were washed in PBS–Tween-20 buffer and in-
cubated with the appropriate HRP-conjugated secondary
antibody. The membranes were visualized by chemilumin-
escence using enhanced chemiluminescence reagents
(GE Healthcare, Little Chalfont, Buckinghamshire, UK).
GAPDH was detected as a protein loading control.
Measurement of intracellular Ca2+ levels
Washed MM cell lines were loaded with 4 μM of fluoro-
chrome fluo-4-acetoxymethyl ester (Fluo-4/AM; Dojindo,
Kumamoto, Japan) in PBS for 1 h at 37°C in the dark.
After washing, the cells were resuspended at a concentra-
tion of 1 × 106 cells/mL. The external Ca2+ level was ad-
justed to 1 mM, and the dyed cells were incubated with
60 μM of CaM antagonists at 37°C for 15 min in the dark
and analyzed by flow cytometry.
Detection of mitochondrial membrane potential
depolarization
A total of 1 × 106 cells were loaded with 10 μg/ml of JC-10
(Cell Meter™ JC-10 Mitochondrial Membrane Potential
Assay Kit; ABD Bioquest Inc., Sunnyvale, CA) at 37°C
for 30 min. Next, the cells were treated with 60 μM of
CaM antagonists at 37°C for 1 h and the visualized
using a fluorescence microscope (Olympus BX-51/DP-72;
Olympus, Tokyo, Japan) fitted with a WIB filter (excita-
tion, 460–490 nm; dichroic mirror, 505 nm; emission
barrier filter, 510 nm).In vivo treatment with CaM antagonists on the RPMI 8226
mouse model
Six-week-old female BALB/c nu mice were purchased
from Charles River Japan (Atsugi, Japan). The animals
were housed under specific pathogen-free conditions
and had free access to food and tap water. All proce-
dures involving these mice were approved by the local
animal ethics committee at Kagawa University. The mice
were inoculated subcutaneously in the flank with 1 × 107
RPMI 8226 cells. Seven days after injection, the mice
were randomly divided into two comparison groups with
10 mice each to ensure proper controls for both agents.
Because W-7 forms insoluble deposits in PBS, it was dis-
solved in water. The comparison groups were the vehicle
(H2O, n = 5) vs. W-7 (dissolved in H2O, n = 5) group
and the vehicle (PBS, n = 5) vs. W-13 (dissolved in PBS,
n = 5) group. The mice were injected intraperitoneally
with H2O, W-7 (3 mg/kg), PBS, or W-13 (3 mg/kg) on 5
consecutive days per week. The tumor sizes were mea-
sured twice weekly in two dimensions using calipers,
and the tumor volume was calculated using the formula
V = 0.5 (a × b2), where a is the long diameter of the
tumor and b is the short diameter of the tumor. The ani-
mals were sacrificed when the tumor diameters reached
2 cm or became ulcerated. After treatment completion,
the xenografts or selected organs (heart, lung, kidney,
liver, and pancreas) were excised, fixed in formalin, em-
bedded in paraffin, and cut into 5.0 μm sections. Adja-
cent sections were stained with hematoxylin and eosin
(H&E) or subjected to a terminal deoxyribonucleotide
transferase–mediated nick-end labeling (TUNEL) assay
(ApopTag In Situ Apoptosis Detection Kit; Intergen,
Purchase, NY). The apoptotic index was calculated as
the number of TUNEL-positive cells divided by the total
number of cells in 10 randomly selected high-power
fields.
Statistical analysis
All values were expressed as means ± standard deviations.
The statistical differences between groups were deter-
mined using paired Student’s t tests. A P value of <0.01
was considered significant.
Results
Calmodulin inhibitors inhibits MM cell proliferation
in vitro
To explore whether CaM antagonists might act as poten-
tial therapeutic agents against MM, we first confirmed
protein expression of CaM in the MM cell lines RPMI
8226, U266, MM1.S, MM1.R, KMS-5, KMS-12BM, and
NCI-H929 by western blot analysis (Figure 1A), and then
determined the effects of the naphthalenesulphonamide
derivatives W-7, W-13, and W-5 (a weaker antagonist for



















































































































































































Figure 1 Effects of CaM antagonists on human multiple myeloma cell proliferation. (A) The basal protein expression levels of CaM in the
multiple myeloma cell lines RPMI 8226, U266, MM1.S, MM1.R, NCI-H929, KMS-12-BM, and KMS-5 were determined by western blot analysis. (B) Cells
were treated with 0–80 μM W-5, W-7, and W-13 for 24 h, after which cell proliferation was assayed according to the WST-8 method.
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presence or absence of CaM antagonists and assessed,
using the WST-8 assay. As shown in Figure 1B, W-7
and W-13 inhibited the proliferation of all MM cell
lines in a dose-dependent manner. The 50% growth
inhibition (IC50) values of W-7 and W-13 ranged from
approximately 45–60 μM and 30–45 μM, respectively,
and W-13 more efficiently inhibited cell proliferation
than an identical concentration of W-7. W-5 had little
effect on MM cell proliferation.Calmodulin antagonists induce G1 phase cell cycle arrest
To determine the mechanisms by which CaM antagonists
inhibited MM cell proliferation, we first investigated the
effects of CaM antagonists on cell cycle progression.
RPMI 8226, U266, and MM1.S cells were treated with
CaM antagonists (40 μM). After 24 h, the cells were ana-
lyzed by flow cytometry. Treatment with W-7 and W-13
increased the percentage of cells in the G0/G1 phase of
the cell cycle and reduced the percentage of cells in the S
phase (Figure 2). Treatment with W-5 had no significant
effect on the cell cycle compared with the control.Effects of CaM antagonists on the expression of cell cycle
regulatory proteins in MM cells
To study the molecular mechanism of G0/G1 phase cell
cycle arrest induced by CaM antagonists, the expression
of various cell cycle-related proteins in MM cells was ex-
amined by western blotting after the cells had been
treated with CaM antagonists (40 μM) for 24 h. As
shown in Figure 3, cyclin D1 expression was reduced
following treatment with W-7 and W-13 in U266 cells;
RPMI 8226 and MM1.S cells lack cyclin D1 [16]. cyclin
D2 and cyclin E1 protein expression was decreased in all
cell lines. In RPMI 8226 cells, CDK2, CDK4 and CDK6
expression was decreased in response to W-7 and W-13.
In U266 cells, CDK2 and CDK4 expression but not
CDK6 expression was decreased. In MM1.S cells, CDK2
and CDK6 expression but not CDK4 expression was de-
creased. p21cip1 protein expression was decreased in all
cell lines. However, the expression levels of p27kip1 and
p53 were unaffected. The levels of phosphorylated Rb
were reduced in RPMI 8226 and MM1.S cells; as some
U266 clones, including ours, exhibit loss of Rb expres-
sion [17]. The same pattern was seen after an incubation
period of 12 h (data not shown).
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Figure 2 Effects of CaM antagonists on the cell cycle in human multiple myeloma cells. Cells were incubated with CaM antagonists (40 μM).








































   pRb
  Rb
p53
Figure 3 Effects of CaM antagonists on the expression of various cell cycle regulatory proteins. Cells were treated with CaM antagonists
(40 μM) for 24 h and then lysed. The lysates were analyzed by western blotting with the indicated antibodies.
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apoptosis in MM cells
We next studied whether CaM antagonists might also
induce apoptosis in MM cells. RPMI 8226, U266 and
MM1.S cells were treated with CaM antagonists (60 μM)
for 24 h, double-stained with annexin-V and propidium
iodide, and analyzed by flow cytometry. The results dem-
onstrated that W-7 and W-13 induced early and late
apoptosis in all MM cell lines (Figure 4).
To explore whether CaM antagonists could induce
apoptosis through caspase-dependent mechanisms, we
performed western blot analysis to examine caspase
activation and poly (ADP-ribose) polymerase (PARP)
cleavage. RPMI 8226, U266 and MM1.S cells were
treated with CaM antagonists (60 μM) for 24 h. The
western blot results indicated caspase-3 and caspase-9
activation and PARP cleavage in W-7 and W-13-treated
RPMI 8226 cells. However, these treatments had no sig-
nificant effects on caspase-8 and caspase-7 activation.
In U266 and MM1.S cells, caspase-8 and caspase-7 ac-
tivation were also observed in addition to caspase-3
and caspase-9 activation and PARP cleavage (Figure 5A).
The same trend, albeit less dramatic, was seen after an
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Figure 4 Effects of CaM antagonists on apoptosis in multiple myeloma
were subsequently harvested and incubated with FITC-labeled annexin V and
flow plots, the lower left quadrant contains normal cells; the lower right quad
late apoptotic and necrotic cells.CaM antagonists promote ERK1/2 phosphorylation in all
MM cells and inhibit STAT3 phosphorylation in U266 and
MM1.S cells
Next, we used western blotting to explore intracellular
signaling proteins associated with cell survival in MM
cells. The cells were treated with CaM antagonists
(60 μM) for 24 h. The western blot analysis revealed that
treatment with W-7 and W-13 promoted ERK1/2 phos-
phorylation in all cell lines and inhibited STAT3 phos-
phorylation in U266 and MM1.S cells but not in RPMI
8226 cells. We also examined the levels of Akt and
phospho-Akt in MM cells treated with CaM antagonists
but found no significant differences in their levels (data
not shown).
Calmodulin antagonists elevate intracellular Ca+2 levels
and induce mitochondrial membrane potential
depolarization
To further evaluate the molecular mechanism that
induced caspase-dependent apoptosis, we examined
intracellular Ca2+ levels and mitochondrial membrane
potential depolarization in response to treatment with
CaM antagonists. MM cells that had been pretreated
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cells. Cells were treated with CaM antagonists (60 μM) for 24 h. The cells
propidium iodide and analyzed by flow cytometry. In the representative












































































Figure 5 Effects of CaM antagonists on apoptosis-related proteins and intracellular signaling proteins. Cells were treated with CaM antagonists
(60 μM) for 24 h and then lysed. The lysates were analyzed by western blotting using the indicated antibodies against proteins related to
caspase-dependent apoptosis (A) and intracellular signaling (B).
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cytometry. Treatment with W-7 and W-13 increased
the intracellular Ca2+ levels in all cell lines (Figure 6A).
The mitochondrial membrane potential was also assessed
using the JC-10 dye. Both W7 and W-13 induced mito-
chondrial membrane potential depolarization in all evalu-
ated cell lines (Figure 6B).
Calmodulin antagonists reduce tumor growth rates in
murine xenograft models
We next investigated the in vivo efficacy of CaM antag-
onists in a MM xenograft mouse model. RPMI 8226
cells were inoculated subcutaneously into the flank of
each BALB/c nu mouse. After the appearance of meas-
urable tumors, the mice were divided into two compari-
son groups: the vehicle (H2O) vs. W-7 (3 mg/kg in
H2O) group and the vehicle (PBS) vs. W-13 (3 mg/kg
in PBS) group. In the vehicle vs. W-7 group, we ended
the experiments on day 25 because of tumor ulceration
in the vehicle-treated mice, and in the vehicle vs. W-13
group, we ended the experiments on day 32 because the
tumor diameters reached 2 cm. Both W-7 and W-13
inhibited tumor growth relative to their respective vehicles
(Figure 7A and B).To examine the in vivo cytotoxic effects of CaM antago-
nists, we performed H&E staining and a TUNEL apoptosis
assay in tumor tissues excised from the mice treated with
vehicle (PBS) or W-13. Although H&E staining showed
that residual MM cells remained in the W-13-treated tu-
mors, TUNEL-positive apoptotic cells were significantly
increased relative to the vehicle-treated tumors (Figure 7C
and D). We also examined the adverse effects of W-13.
No significant changes in complete blood count, body
weight, or other appearances of toxicity were observed in
the animals (Figure 7E). In addition, pathological screen-
ing of the H&E sections of heart, lung, liver, kidney, and
pancreas showed no apparent changes in the W-13-
treated animals, except for in one mouse who had slight
inflammation in the pancreas (Figure 7F).Discussion
In the present study, we have shown that CaM antago-
nists inhibited MM cell proliferation in vitro and
in vivo, and to elucidate the mechanisms of action of
CaM antagonists, we have revealed two cellular and
molecular mechanisms: induction of cell cycle arrest
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Figure 6 Effects of CaM antagonists on intracellular Ca2+ levels and mitochondrial membrane potential. (A) Cells were loaded with 4 μM
Fluo-4/AM dye for 1 h, after which the dyed cells were incubated with CaM antagonists (60 μM) for 30 min. The intracellular Ca2+ levels were analyzed
by flow cytometry. Data are expressed as means ± standard deviations. *P <0.01 for the comparison with control cells. (B) Cells were pretreated with
JC-10 dye for 30 min, and subsequently incubated with CaM antagonists (60 μM) for 1 h. The cells were then visualized under a fluorescence
microscope to visualize the yellow fluorescent aggregation that indicates high mitochondrial membrane potential which is distinct from the
green fluorescent monomer observed at a low mitochondrial membrane potential.
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could markedly induce G1 phase arrest in MM cells.
Cell cycle progression is driven by the activation of spe-
cific cyclin– CDK complexes at different intervals. The
formation of complexes between D-type cyclins and
CDK4 and CDK6 is required for G1 phase progression
[18]. CaM has been shown to be essential for CDK4 acti-
vation and nuclear cyclin D1–CDK4 complex accumula-
tion during the G1 phase [19], and recent research has
shown that CaM competes with F-box protein FBXL-2,
which promotes ubiquitination and degradation of cyclin
D2 [20]. It therefore seems reasonable to suppose thatCaM antagonists would inhibit the activities of cyclin
D–CDK4/CDK6 complexes in MM cell lines.
We also revealed that cyclin E–CDK2 complex for-
mation was downregulated in response to treatment with
CaM antagonists. Complex formation between cyclin E
and CDK2 is rate limiting and essential for S phase entry
[21]. Human cyclin E genes have been reported to contain
a CaM-binding motif, and CaM has a direct stimulatory
effect on cyclin E–CDK2 [22]. Furthermore, the down-
regulated CDK2 expression was previously observed in
response to treatment with the CaM antagonist W-13
in a T lymphocyte-based experiment [23]. Together,
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Figure 7 In vivo antitumor effects of CaM antagonists in a murine multiple myeloma xenograft model. RPMI 8226 cells were implanted
subcutaneously into the flanks of nude mice. Seven days later, 3 mg/kg of CaM antagonists were injected intraperitoneally on 5 days in per week.
The tumor sizes were measured twice weekly. The comparison groups were the vehicle (H2O) vs. W-7 group (A) and the vehicle (PBS) vs. W-13
group (B). The photographs show representative mice, and arrows indicate the tumors. Tumor tissue sections from the mice treated with vehicle
or W-13 were stained with hematoxylin/eosin (H&E) or terminal transferase dUTP nick-end labeling (TUNEL) staining (C). TUNEL-positive apoptotic
cells were counted in 10 random high power fields (D). Complete blood count and body weight (BW) were also examined in the mice exposed
to vehicle or W-13 (E). Data are from five independent animals and are expressed as the mean ± standard deviation. *P <0.01 compared with
vehicle. Histology sections of selected organs from the mice treated with vehicle or W-13 were stained with H&E, and representative tissue section
of each organ was shown (F).
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vation of cyclin E–CDK2 complexes.
p21cip1 is a potent cyclin-dependent kinase inhibitor
that binds to and inhibits the activities of CDKs and
thus functions as a regulator of cell cycle progression
through the G1 and S phases [24]. CaM antagonists have
been shown to induce sustained ERK1/2 activation and
p21cip1 overexpression [25]. Sustained ERK pathway acti-
vation induces cell cycle arrest, whereas transient ERK
activation is a common feature of cell proliferation inmany systems [26]. This dual effect of ERK1/2 on cell
proliferation has been shown to depend on p21cip1 ex-
pression [27,28]. The ERK pathway also induces the
expression of the positive cell cycle regulator cyclin D1.
The inability to induce cell proliferation following a
strong ERK activation is associated with a lack of cyclin
D1 induction [29]. In agreement with that earlier find-
ing, our results showed that CaM antagonist-induced
ERK1/2 activation correlated with p21cip1 overexpression
in the absence of cyclin D1 upregulation.
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MM cell proliferation is caspase-dependent apoptosis.
Apoptotic pathways can be divided into those that
involve extrinsic death receptor signaling with the acti-
vation of the initiator caspase-8 and those that involve
intrinsic mitochondrial damage with the activation of
the initiator caspase-9 [30]. Our data revealed that CaM
antagonists induced the activation of caspase-8 and
caspase-7 in U266 and MM1.S cells but not in RPMI
8226 cells and the activation of caspase-9 and caspase-3
in all MM cell lines, suggesting that CaM antagonists
induced apoptosis via the extrinsic pathway in U266 and
MM.S cells and via the intrinsic pathway in all cell lines.
Recent studies have suggested that frequent activation
of STAT3 signaling provides a survival advantage to
MM cells [31-33] and that the STAT3 pathway mediates
the induction of antiapoptotic proteins such as Mcl-1,
Bcl-2, and Bcl-xL. Of these antiapoptotic proteins, Mcl-1
is an essential survival factor [34]. Our data revealed
that STAT3 phosphorylation was inhibited in response
to treatment with CaM antagonists, thus leading to re-
duced Mcl-1 protein expression in U266 and MM1.S
cells but not in RPMI 8226 cells. We therefore assumed
that the differences between the MM cell lines in terms
of the extrinsic apoptotic pathway resulted from the
inhibition of STAT3 phosphorylation. The mechanism
associated with the differences in STAT3 inactivation in
the different cell lines is unclear and will require further
investigation.
The elevated intracellular Ca2+ level and mitochon-
drial membrane potential depolarization observed in
our research comprise still another identified molecular
event identified associated with CaM antagonist-mediated
apoptosis. Naphthalenesulphonamide derivative CaM an-
tagonists have been shown to induce increases in the
intracellular Ca2+ levels in several cell types [35-37]. A
sustained increases in the cytosolic Ca2+ levels leads to
the collapse of the mitochondrial membrane potential
via Ca2+ overloading of the mitochondria [38]. After
mitochondrial depolarization, cytochrome c is released
to accumulate in the cytoplasm, followed by caspase-9
and caspase-3 activation, which cleaves PARP and ul-
timately leads to apoptosis [28].
Finally, CaM antagonists were well tolerated and very
effective in an in vivo murine MM model, as evidenced
by the inhibition of MM tumor growth in mice injected
intraperitoneally with CaM antagonists. In particular,
W-13 inhibited tumor growth more effectively than W-7
at the same dosage. Surprisingly, relatively low dose of
W-13 was very effective compared with the high IC50
value in vitro. We assume that the efficacy in vivo is
partly due to the fact that W-7 and W-13 possess highly
water-soluble and cell-permeable properties and seem to
have high bioavailability. W-7 and W-13 have beenreported to inhibit the formation of bovine erythroid col-
onies [39]. However, no significant change in complete
blood count was observed in the W-13-treated animals.
Pathological screening of the H&E sections of heart, lung,
liver, kidney, and pancreas showed no apparent changes in
the W-13-treated animals, except for in one mouse who
had slight inflammation in the pancreas. This inflamma-
tion may be associated with the intraperitoneal injection
of the drugs.
It is important to mention that there are potential off-
target effects of CaM antagonists, and some pharmaco-
logical effects of CaM antagonists might not be mediated
solely via the direct inhibition of CaM. In addition, our
animal model reflects a plasmacytoma model and repre-
sents a minority of clinical myeloma cases. Therefore,
further experimental studies are needed to address these
limitations.
Conclusions
We have shown that CaM antagonists induce cell cycle
arrest, induce apoptosis via caspase activation, and inhibit
tumor growth in a murine MM model. These results raise
the possibility that inhibition of CaM might be a useful
therapeutic strategy for the treatment of MM.
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